BIFURCATION ANALYSIS IN A SEROGROUP A MENINGOCOCCAL INFECTION MODEL

被引:1
|
作者
Bah, Alpha Oumar [1 ]
Lam, Mountaga [1 ]
Bah, Alassane [2 ]
Bowong, Samuel [3 ]
机构
[1] Univ Cheikh Anta Diop, Dept Math, Fac Sci & Tech, Dakar, Senegal
[2] Univ Cheikh Anta Diop, Natl Adv Sch Engn, Dept Comp Engn, Dakar, Senegal
[3] Univ Douala, Fac Sci, Dept Math & Comp Sci, Lab Math, POB 24157, Douala, Cameroon
关键词
epidemiological models; serogroup A meningococcal infection; stability; bifurcation; NEISSERIA-MENINGITIDIS; BACKWARD BIFURCATION; SENSITIVITY-ANALYSIS; VACCINATION; DISEASE; EPIDEMIC; TUBERCULOSIS; W135; TRANSMISSION; UNCERTAINTY;
D O I
10.28919/cmbn/3760
中图分类号
TP [自动化技术、计算机技术];
学科分类号
0812 ;
摘要
A mathematical model is formulated that enables the understanding of the dynamics of the transmission of serogroup A meningococcal (MenA) infection. We provide the theoretical analysis of the model. We compute the basic reproduction number R-0 and shows that the outcome of the disease depends on a threshold parameter xi. More precisely, we show that when R-0 <= xi, the disease-free equilibrium is globally asymptotically stable, while when xi <= R-0 <= 1, the model exhibits the phenomenon of backward bifurcation, when a stable diseasefree equilibrium co-exists with one or more stable endemic equilibria. Sensitivity analysis of the model has been performed in order to determine the impact of related parameters on meningitis outbreak. Random perturbation of the vaccine efficacy was performed to gain insight into the role of the vaccine efficacy on the stability of the disease-free equilibrium. Theoretical results are supported by numerical simulations, which further suggest that the control of the epidemic of MenA pass through a combination of a large coverage vaccination of young susceptible individuals and the production of a vaccine with a high level of efficacy.
引用
收藏
页数:38
相关论文
共 50 条
  • [11] Serogroup Y meningococcal disease, Colombia
    Agudelo, Clara Ines
    Sanabria, Olga Marina
    Ovalle, Maria Victoria
    EMERGING INFECTIOUS DISEASES, 2008, 14 (06) : 990 - 991
  • [12] Serogroup A meningococcal conjugate vaccines in Africa
    Kristiansen, Paul A.
    Jorgensen, Hannah J.
    Caugant, Dominique A.
    EXPERT REVIEW OF VACCINES, 2015, 14 (11) : 1441 - 1458
  • [13] Prevention of serogroup B meningococcal disease
    Stephens, David S.
    LANCET, 2012, 379 (9816): : 592 - 594
  • [14] The burden of serogroup B meningococcal disease
    van de Beek, Diederik
    LANCET NEUROLOGY, 2012, 11 (09): : 743 - 745
  • [15] The Endgame for Serogroup A Meningococcal Disease in Africa?
    Maiden, Martin C. J.
    CLINICAL INFECTIOUS DISEASES, 2013, 56 (03) : 364 - 366
  • [16] Trumenba: A Serogroup B Meningococcal Vaccine
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2015, 57 (1459): : 5 - 6
  • [17] An effective serogroup B meningococcal vaccine
    Dominguez, Francisco
    Menendez, Jorge
    Ochoa, Rolando
    VACCINE, 2006, 24 (49-50) : 7025 - 7026
  • [18] Meningococcal serogroup C conjugate vaccine
    Lakshman, R
    Finn, A
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2002, 2 (01) : 87 - 96
  • [19] Stability and bifurcation analysis in a viral infection model with delays
    Sun, Xinguo
    Wei, Junjie
    ADVANCES IN DIFFERENCE EQUATIONS, 2015,
  • [20] Bifurcation analysis of multistability and hysteresis in a model of HIV infection
    Mironov, I. V.
    Khristichenko, M. Yu.
    Nechepurenko, Yu. M.
    Grebennikov, D. S.
    Bocharov, G. A.
    VAVILOVSKII ZHURNAL GENETIKI I SELEKTSII, 2023, 27 (07): : 755 - 767